Bradley A. Keywell Sells 395,800 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 395,800 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares in the company, valued at $694,263,084.55. This represents a 2.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Tempus AI Trading Down 2.4 %

Shares of Tempus AI stock opened at $41.00 on Friday. The business has a 50-day moving average price of $52.64. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TEM shares. Bank of America raised their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday. Loop Capital raised their price objective on Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. Guggenheim initiated coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Wolfe Research began coverage on shares of Tempus AI in a research note on Friday. They issued an “outperform” rating and a $60.00 price objective for the company. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of TEM. First Horizon Advisors Inc. purchased a new position in Tempus AI in the third quarter worth $30,000. Sandia Investment Management LP purchased a new position in Tempus AI during the 2nd quarter worth $136,000. Vestor Capital LLC purchased a new position in Tempus AI during the 3rd quarter worth $153,000. Stifel Financial Corp acquired a new position in Tempus AI during the 3rd quarter valued at about $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Tempus AI in the third quarter valued at about $258,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.